(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...

Parker Waichman, a national law firm, along with four other law firms, asks the New Jersey Supreme Court to Centralize all Ozempic/Wegovy NAION New Jersey ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, ...

Texas Attorney General Ken Paxton is accusing Eli Lilly and Co. of a kickback scheme to induce medical providers to prescribe ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...

Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

( NewsNation) — New research suggests popular weight loss drugs like Ozempic and Wegovy may affect more than just fat, ...

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...

On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 2, 2025, thereby injuring investors. What Is The Lawsuit About?